Filing Flows › Comparisons › SNY vs JNJ
Sanofi vs Johnson & Johnson: SNY and JNJ compared
Sanofi is the larger company: $43.6B of revenue in its latest quarter (FY2025) against $25.4B for Johnson & Johnson (Q3 2026). Sanofi is growing faster (+6% against +6% a year earlier). Sanofi is more profitable, with an operating margin of 14.5% against 0.1%.
Where the money goes: SNY and JNJ
Sanofi (SNY) · FY2025
Sanofi, FY2025: revenue $43.6B (+6% year over year), operating margin 14.5%, net earnings $7.8B, operating cash flow $10.8B. The chart follows the revenue to costs, profit and cash.
Johnson & Johnson (JNJ) · Q3 2026
Johnson & Johnson, Q3 2026: revenue $25.4B (+6% year over year), operating margin 0.1%, net earnings $210M, operating cash flow $7.7B. The chart follows the revenue to costs, profit and cash.
| Sanofi (SNY) | Johnson & Johnson (JNJ) | |
|---|---|---|
| Latest quarter | FY2025 | Q3 2026 |
| Revenue | $43.6B | $25.4B |
| Revenue growth, Y/Y | +6% | +6% |
| Gross margin | 77.2% | 68.1% |
| Operating margin | 14.5% | 0.1% |
| Net earnings | $7.8B | $210M |
| Net margin | 17.9% | 0.8% |
| Operating cash flow | $10.8B | $7.7B |
| Free cash flow | — | $6.4B |
| Market value | $57.4B | $676.4B |
| P/E | — | 42.0× |
| Analysts’ mean target | $53.48 | $279.41 |
Where the revenue comes from
Johnson & Johnson
- Innovative Medicine: $16.8B (66%)
- MEDTECH: $8.6B (34%)
Questions
Which is bigger, Sanofi or Johnson & Johnson?
Sanofi is the larger company: $43.6B of revenue in its latest quarter (FY2025) against $25.4B for Johnson & Johnson (Q3 2026).
Is Sanofi or Johnson & Johnson growing faster?
Sanofi is growing faster (+6% against +6% a year earlier).
Which is more profitable, Sanofi or Johnson & Johnson?
Sanofi is more profitable, with an operating margin of 14.5% against 0.1%.
More: Sanofi earnings · how Sanofi makes money · Johnson & Johnson earnings · how Johnson & Johnson makes money
From the companies' latest 10-Q, 10-K or earnings release (20-F filed Feb 17, 2026; 10-Q filed Oct 21, 2026). Fiscal quarters can end on different dates. Not investment advice.